CAM advised the lead managers, JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited in connection with the IPO of Anthem Biosciences Limited. Anthem is an innovation-driven and technology-focused contract research, development and manufacturing organization, with fully integrated operations spanning across drug discovery, development and manufacturing.
It was a pure offer for sale of equity shares by certain existing shareholders, aggregating to ₹ 33,950 million. The equity shares were listed on the stock exchanges on July 21, 2025. The issue was oversubscribed 63.86 times, reflecting a premium of 26.85% over the issue price of ₹570.
The transaction team was led by Reuben Chacko, Partner (Regional Co-Head – Capital Markets – South); and Vartika Jain, Partner; with assistance from Bhaskar Kumar, Associate, Dhruv Sharma, Associate; Prakhar Jain, Associate; Joe George, Associate; and Rakshitha V, Associate.
